Suppr超能文献

“PoCOsteo设备”的初步多中心验证方案:一种用于骨质疏松症蛋白质组学和基因组学研究的床旁检测工具。

Protocol for preliminary, multicenteric validation of "PoCOsteo device": A point of care tool for proteomic and genomic study of osteoporosis.

作者信息

Razi Farideh, Ostovar Afshin, Fahimfar Noushin, M Amoli Mahsa, Fana Saeed Ebrahimi, Dimai Hans Peter, Obermayer-Pietsch Barbara, Luegger Barbara, Rivadeneira Fernando, Nabipour Iraj, Larijani Bagher, Khashayar Patricia

机构信息

Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Biol Methods Protoc. 2024 Mar 22;9(1):bpae006. doi: 10.1093/biomethods/bpae006. eCollection 2024.

Abstract

One of the goals of the HORIZON 2020 project PoCOsteo was to develop a medical device, which would measure and/or quantify proteomic as well as genomic factors as present in whole blood samples collected through finger prick. After validating the tool in the clinical setting, the next step would be its clinical validation based on the existing guidelines. This article presents the protocol of a validation study to be carried out independently at two different centers (Division of Endocrinology and Diabetology at the Medical University of Graz as a clinic-based cohort, and the Endocrinology and Metabolism Research Institute at the Tehran University of Medical Sciences as a population-based cohort). It aims to assess the tool according to the Clinical & Laboratory Standards Institute guidelines, confirming if the proteomics and genomics measurements provided by the tool are accurate and reproducible compared with the existing state-of-the-art tests. This is the first time that such a detailed protocol for lab validation of a medical tool for proteomics and genomic measurement is designed based on the existing guidelines and thus could be used as a template for clinical validation of future point-of-care tools. Moreover, the multicentric cohort design will allow the study of a large number of diverse individuals, which will improve the validity and generalizability of the results for different settings.

摘要

“地平线2020”项目PoCOsteo的目标之一是开发一种医疗设备,该设备能够测量和/或量化通过手指采血采集的全血样本中存在的蛋白质组学和基因组学因素。在临床环境中验证该工具后,下一步将根据现有指南对其进行临床验证。本文介绍了一项将在两个不同中心独立开展的验证研究方案(格拉茨医科大学内分泌与糖尿病科作为基于诊所的队列,德黑兰医科大学内分泌与代谢研究所作为基于人群的队列)。其目的是根据临床与实验室标准协会的指南对该工具进行评估,确认该工具提供的蛋白质组学和基因组学测量结果与现有最先进测试相比是否准确且可重复。这是首次基于现有指南设计如此详细的用于蛋白质组学和基因组测量医疗工具实验室验证的方案,因此可作为未来即时检测工具临床验证的模板。此外,多中心队列设计将允许对大量不同个体进行研究,这将提高不同环境下结果的有效性和普遍性。

相似文献

本文引用的文献

9
Romosozumab: First Global Approval.罗莫索单抗:全球首次获批。
Drugs. 2019 Mar;79(4):471-476. doi: 10.1007/s40265-019-01072-6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验